skip to main content

Inhaled antimuscarinic caution — GPhC CRA MCQ

Instant feedback + full explanation. One question, done properly.

HardRespiratory TherapeuticsInhaled antimuscarinic cautionGPhC CRA

A man with COPD and bladder-outlet obstruction started umeclidinium one week ago. He now has suprapubic pain and has been unable to pass urine for 10 hours. What should the pharmacist do?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Arrange urgent assessment for acute urinary retention and withhold further umeclidinium pending review

Explanation lettering: E = shown as A · A = shown as C · C = shown as E

A would intensify the suspected antimuscarinic adverse effect. B is correct: painful inability to void is acute urinary retention requiring urgent assessment; further umeclidinium should not be taken until the regimen is reviewed. C adds another anticholinergic medicine. D misinterprets a recognised urinary adverse reaction. E delays care and fluid restriction does not relieve obstruction.

Reference: Incruse Ellipta SmPC. https://www.medicines.org.uk/emc/product/3418/smpc